Clinical pharmacology of anticancer drugs.
D000818:Animals; D000970:Antineoplastic Agents / Q000378:metabolism / Q000627:therapeutic use*; D001374:Azacitidine / Q000627:therapeutic use; D001761:Bleomycin / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D003606:Dacarbazine / Q000494:pharmacology; D003630:Daunorubicin / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D006321:Heart / Q000187:drug effects; D006801:Humans; D002955:Leucovorin / Q000627:therapeutic use; D008168:Lung / Q000187:drug effects; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D009369:Neoplasms / Q000188:drug therapy; D009607:Nitrosourea Compounds / Q000627:therapeutic use; D011344:Procarbazine / Q000627:therapeutic use; D014226:Triazenes / Q000627:therapeutic use; D014747:Vinblastine / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
D000970:Antineoplastic Agents; D009607:Nitrosourea Compounds; D014226:Triazenes; D003561:Cytarabine; D001761:Bleomycin; D011344:Procarbazine; D014750:Vincristine; D014747:Vinblastine; D003606:Dacarbazine; D004317:Doxorubicin; D003520:Cyclophosphamide; D001374:Azacitidine; D002955:Leucovorin; D005472:Fluorouracil; D008727:Methotrexate; D003630:Daunorubicin